Current disease status-Recurrent leukemia - Page 5 of 8 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent leukemia Posts on Medivizor

How safe and effective is ponatinib for chronic phase chronic myeloid leukemia patients?

Posted by on Apr 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness and safety of ponatinib (Iclusig) for patients with chronic phase chronic myelogenous leukemia. This study concluded that ponatinib is safe and effective in this group of patients. Some background The Philadelphia chromosome (BCR-ABL1) is found in almost all patients with chronic...

Read More

A new option for chronic myeloid leukemia patients who have an intolerance to TKIs

Posted by on Mar 27, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of nilotinib (Tasigna) in patients with chronic phase chronic myeloid leukemia who have an intolerance to other tyrosine kinase inhibitors. This study concluded that this group of patients can be treated with nilotinib and it can lead to deep molecular responses. Some background...

Read More

Risk factors that influence outcomes for acute leukemia patients with relapse after hematopoietic stem cell transplant.

Posted by on Mar 17, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate risk factors that influence the outcome of acute leukemia patients who experience relapse after hematopoietic stem cell transplant. This study concluded that certain factors, such as older age and not acheiving remission after relapse treatment, are associated with worse survival outcomes. Some...

Read More

17p deletion and 8q24 gain: Two chromosomal abnormalities that can predict outcomes

Posted by on Mar 11, 2018 in Leukemia | 0 comments

In a nutshell This study examined causes and outcomes of a chromosomal abnormality known as 17p deletion in chronic lymphocytic leukemia (CLL). Researchers reported poor outcomes for patients that have both 17p deletion and 8q24 gain. Some background Certain genetic changes in CLL can make it more difficult to treat. Changes in the chromosomes, such...

Read More

Ibrutinib in combination with bendamustine and rituximab improves quality of life factors in patients with severe impairment

Posted by on Feb 24, 2018 in Leukemia | 0 comments

In a nutshell This study examined how treatment with ibrutinib (Imbruvica), rituximab (Rituxan), and bendamustine (Treanda) impacts quality of life in chronic lymphocytic leukemia (CLL) patients. Factors such as fatigue, physical functioning, and well-being were all improved among those patients with the lowest scores before treatment. Some background...

Read More

What effect do different stem cell types have in transplantation for patients with acute leukemia?

Posted by on Feb 15, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the effect of stem cell source on haploidentical transplantation with post-transplantation cyclophosphamide (a chemotherapy) in patients with acute leukemia. This study concluded that the use of peripheral blood stem cells increases the risk of side effects for these patients. Some background Patients...

Read More

An overview of the dose management of dasatinib

Posted by on Feb 5, 2018 in Leukemia | 0 comments

In a nutshell This study reviewed evidence on the dose management of dasatinib (Sprycel) for chronic myeloid leukemia (CML). Some background Tyrosine kinase inhibitor (TKI) therapy is a standard first-line treatment for CML. Many patients achieve optimal response to TKI therapy and have a near-normal life expectancy. However, this response is lost...

Read More

Looking for participants with relapse of childhood B-lymphoblastic leukemia to receive blinatumomab

Posted by on Feb 5, 2018 in Leukemia | 0 comments

In a nutshell This phase 3 trial aims to determine the effect of blinatumomab compared to standard chemotherapy in treating patients with B-cell acute lymphoblastic leukemia after a relapse (return of cancer after a period of improvement). The outcome to be measured is the survival rate over 10 years.  The details Acute lymphoblastic leukemia...

Read More

Combined haploidentical-cord stem cell transplantation in lymphoma and CLL – what are the outcomes?

Posted by on Jan 30, 2018 in Leukemia | 0 comments

In a nutshell This study analyzed the outcomes of lymphoma and chronic lymphoblastic leukemia (CLL) patients who received haplo-cord stem cell transplantation. The study concluded that this method gives higher rates of engraftment and lower rates of graft-versus-host disease (GVHD) compared to haploidentical transplant. Some background High-risk...

Read More